Investment in Cell and Gene Therapy - Landing Page
HemaCare & Cellero
HemaCare, a Charles River company, is a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cell and gene therapy development. HemaCare’s vertically integrated solutions support preclinical research, clinical studies, and commercialization with high-quality RUO and GMP-compliant starting material, isolated cells, and apheresis collections. Join our team where every day is an opportunity to advance discoveries and make a difference in someone’s life.
Cellero delivers the most reliable biomaterials and custom research and clinical laboratory services to advance the discovery and development of new treatments and cures. Our expertise in immune cell biology, biomaterial collections, and cell characterization makes Cellero an indispensable partner for early-stage research, clinical trials, manufacturing, commercialization, and treatment delivery.
Cognate Biosciences & Cobra Biologics
Charles River has added premier development and manufacturing capabilities to our comprehensive portfolio of support for cell and gene therapy programs. Our acquisition of Cognate BioServices and its Cobra Biologics facilities help us offer a unique end-to-end solution for the development and delivery of novel cell and gene therapies[BJ1] .
Cognate and Cobra’s wide range of starting materials, comprehensive manufacturing solution for cell therapies, and production of plasmid DNA for gene therapies augment our existing line of human cellular products (via HemaCare and Cellero) and biologics testing solutions, completing the development lifecycle. We help take cell and gene therapies from early research and discovery all the way through commercialization in a single, streamlined program for our clients.
Cognate’s commercial-scale cGMP-compliant Cell Therapy Manufacturing Facilities are located in Memphis, TN, and their Life Science hub is located in Baltimore, MD. Cobra’s Viral Vector & Plasmid DNA Manufacturing facilities are located in Keele, UK and Matfors, Sweden.
Vigene Biosciences
With the acquisition of Vigene Biosciences, a leading contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions, we further strengthened our ability to support our clients with end-to-end cell and gene therapy support
Vigene has significant expertise in CGMP viral vector manufacturing of adeno-associated viruses (AAV), the most commonly used delivery solution for gene therapies, as well as other major viral vectors, including lentivirus, retrovirus and adenovirus. Vigene also specializes in producing high-quality, research grade, and CGMP plasmid DNA, a fundamental tool used in the development of viral vectors for gene-modified cell therapies, gene therapies, and vaccine production.
With operations based in Rockville, MD, Vigene expands and complements our viral vector and plasmid DNA offerings in Europe (with the acquisition of Cobra Biologics). When combined with our integrated portfolio of Biologics Testing Solutions, we now offer a comprehensive solution from discovery and non-clinical development through CGMP manufacturing in advanced drug modalities.
